Abstract | Pancreatic neuroendocrine tumours (PNETs) might occur as a non-familial isolated endocrinopathy or as part of a complex hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1). MEN1 is an autosomal dominant disorder characterized by the combined occurrence of PNETs with tumours of the parathyroids and anterior pituitary. Treatments for primary PNETs include surgery. Treatments for non-resectable PNETs and metastases include biotherapy (for example, somatostatin analogues, inhibitors of receptors and monoclonal antibodies), chemotherapy and radiological therapy. All these treatments are effective for PNETs in patients without MEN1; however, there is a scarcity of clinical trials reporting the efficacy of the same treatments of PNETs in patients with MEN1. Treatment of PNETs in patients with MEN1 is challenging owing to the concomitant development of other tumours, which might have metastasized. In recent years, preclinical studies have identified potential new therapeutic targets for treating MEN1-associated neuroendocrine tumours (including PNETs), and these include epigenetic modification, the β-catenin-wingless (WNT) pathway, Hedgehog signalling, somatostatin receptors and MEN1 gene replacement therapy. This Review discusses these advances.
Pancreatic neuroendocrine tumours (PNETs) have a reported incidence of 0.48 per 100,000 people in the United States, although they are found more frequently in patients undergoing post-mortem examinations (0.8-1.0%) [1] [2] [3] . PNETs usually occur as a non-familial (that is, sporadic) isolated endocrinopathy, but they can also occur as part of a complex hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1)
, von Hippel-Lindau disease (VHL), neurofibromatosis 1 (NF1; previously known as von Recklinghausen's syndrome) and tuberous sclerosis 4, 5 . PNETs have been reported to occur in 30-80% of patients with MEN1, >15% of patients with VHL, <10% of patients with NF1 and <1% of patients with tuberous sclerosis 5, 6 . Thus, MEN1 is the most common hereditary syndrome associated with PNETs, and ~10% of all PNETs are associated with MEN1 (REF. 7 ). Moreover, somatic mutations of the MEN1 gene, which are found in almost all PNETs in patients with MEN1 (REF. 8 ), are also found in >40% of sporadic PNETs, indicating that MEN1 mutations are major drivers in the development of all PNETs 9, 10 . Current treatment for PNETs include drugs (for example, chemotherapy and biotherapies), surgery and radiotherapy (BOXES 1,2; FIG. 1 ). These treatments are often not successful, such that the median survival time for patients with PNETs is ~3.6 years 1 . Thus, there is a clinically unmet need for better treatments, which might arise from a greater understanding of PNET biology and the role of the MEN1 gene and its encoded protein menin. This Review focuses on providing an overview of the clinical features (FIG. 2) and genetics of MEN1, the functions of menin (FIG. 3) , the current therapies for PNETs in patients without MEN1 and their use in treating PNETs in patients with MEN1 (BOX 2; Supplementary information Table 1 ) and emerging therapies, some of which are based on the function of menin (FIG. 3) .
Multiple endocrine neoplasia type 1 MEN1 is characterized by the combined occurrence of two or more tumours that usually involve the parathyroids, pancreatic islets, anterior pituitary and adrenals 11 (BOX 1; FIG. 2a-c) . In addition, <5% of patients with MEN1 develop carcinoid tumours of the thymus, bronchus and gut, and female patients with MEN1 might have an increased occurrence of breast cancer 11, 12 . The majority of patients with MEN1 will have developed manifestations of an MEN1-related tumour by the age of 45 years 13 .
Primary hyperparathyroidism (PHPT), caused by parathyroid tumours, is the most common manifestation (occurring in >80% of patients with MEN1 by the age of 50 years) 14 . Among the pancreatic islet cell tumours, which are also referred to as PNETs, ~60% will secrete polypeptide hormones such as gastrin, insulin, glucagon and vasoactive intestinal peptide (VIP) and cause multiple ulcers of the stomach and duodenum, hypoglycaemia with seizures, glucose intolerance and watery diarrhoea with hypokalaemic alkalosis (WDHA) syndrome, respectively 15, 16 . However, 40% of these PNETs might not secrete hormones, and these are referred to as non-functioning (that is, non-secreting) PNETs 11, 15, 16 . Approximately 90% of anterior pituitary tumours in patients with MEN1 will secrete prolactin, growth hormone (GH) or adrenocorticotropic hormone (ACTH), and the remaining ~10% are non-functioning (or glycoprotein-subunit-secreting) adenomas 11, 16 . For adrenal cortical tumours in patients with MEN1, ~10% will hypersecrete glucocorticoids or mineralocorticoids, while ~90% will be non-functioning 17 . The majority of MEN1-associated endocrine tumours that hypersecrete hormones are benign adenomas 17 . However, as a consequence of hormone hypersecretion, hormone-related disorders will result in specific symptoms and morbidities in patients with MEN1 that might not always be similar to those in patients without MEN1 (REFS 11, 16) . This is because patients without MEN1 will have a tumour in only one endocrine gland, whereas patients with MEN1 will have tumours occurring in two or more glands (FIG. 2a-d ). These endocrine tumours in patients with MEN1 are associated with a decreased 20-year survival of <65% compared with a >80% 20-year survival in an age-matched and sex-matched US population 18 .
Genetics of MEN1
MEN1 is an autosomal dominant disorder caused by mutations of the MEN1 tumour suppressor gene, which encodes a 610-amino-acid protein called menin
. MEN1 germline mutations are found in >90% of patients with MEN1 (REFS 8, 11) , comprise whole or partial gene deletions, frameshift deletions or insertions, in-frame deletions or insertions and splice site, missense and nonsense mutations and result in a functional deficiency of menin 11 . There seem to be no genotype-phenotype correlations 8, 19, 20 . MEN1 tumours will have somatic mutations and germline mutations, which is consistent with the Knudson two-hit hypothesis for the role of tumour suppressor genes in oncogenesis. In the majority of MEN1 tumours (>90%), the somatic abnormality is caused by loss of heterozygosity (LOH), with the remaining 10% having intragenic deletions or point mutations 11, 18, 21, 22 . Moreover, the somatic mutations of the MEN1 gene are also involved in the aetiology of non-MEN1 parathyroid tumours (~20%), PNETs (~40%), pituitary adenomas (~4%) and adrenal cortical adenomas (~2%) 11, 17 .
Current treatment of MEN1 tumours
Antitumour therapies comprise medical, surgical and radiological approaches (BOXES 1,2; FIG. 1). Choosing the optimal treatment for patients with MEN1 endocrine tumours is frequently challenging as such therapies have not been formally evaluated with clinical trials in patients with MEN1 but instead have often been extrapolated from outcomes of clinical trials reported from patients without MEN1 who are affected with only a single endocrine tumour 17 (Supplementary information Table 1 ). This lack of specific trials increases the reliance on consensus expert opinions, which acknowledge the uncertainties in the provisions of optimal treatments. However, it is recognized that in the absence of treatment, endocrine tumours in patients with MEN1 are associated with decreased life expectency 17 . Thus, untreated patients with MEN1-associated tumours have a 50% probability of death by the age of 50 years 17 . The cause of death in 50-70% of patients with MEN1 is usually a malignant tumour-related process or sequelae of the disease 21, 22 . This increased mortality in patients with MEN1 can be attributed to PNETs, which might metastasize 21, 22 . However, the implementation of genetic diagnoses and regular screening for MEN1-associated tumours has resulted in their earlier detection and treatment 17 . This has caused a shift towards less-advanced clinical presentations in patients with MEN1 undergoing screening than in those who are unscreened, with lower rates of malignant PNETs (0% versus 14%), metastases (0% versus 7%) and death (0% versus 7%) 23 . PNETs in patients with MEN1 are usually diagnosed between >10 and 50 years of age. Despite the tumours being small (that is, <1 cm), PNETs frequently appear in multiples and occur on a background of diffuse microadenomatosis 24, 25 . In addition, PNETs in patients with MEN1 occur concomitantly with other tumours, and the associated comorbidities might also decrease survival 22 . The mean age of death for patients with MEN1 and PNETs is 55 years, which is lower than that expected for the general population. Approximately 40% of these deaths are due to malignant PNETs, which are usually non-functioning PNETs, and are not associated with a clinical syndrome 21, 22 . These non-functioning PNETs in patients with MEN1 are invariably located within the pancreas and will be associated with lymph
Key points
• Patients with multiple endocrine neoplasia type 1 (MEN1) can develop hormone-secreting and non-hormone-secreting tumours in endocrine organs, including in the pancreas, which decreases their life expectancy substantially • Pancreatic neuroendocrine tumours (PNETs) in patients with MEN1 are especially difficult to treat owing to differences in growth potential, concomitant development of other tumours and relative insensitivity to treatment • Current medical, surgical and radiological treatments for MEN1-related PNETs have not been formally assessed but instead have been used on the basis of their effects on PNETs in patients without MEN1 • Therapies targeting MEN1-related tumours are required, and preclinical studies indicate that gene therapy, epigenetic modifiers, and wingless (WNT) pathway and vascular endothelial growth factor (VEGF)-signalling antagonists might be promising treatments • Chemoprevention aimed at reducing or delaying the occurrence of MEN1-related PNETs might be possible by chronic administration of somatostatin analogues, which have anti-proliferative and anti-secretory actions node (~33%) and hepatic metastases (15%) 25, 26 . Nonfunctioning PNETs are the most common cause of death in patients with MEN1, with 5-year and 10-year survival being ~75% and ~50%, respectively [27] [28] [29] . By contrast, non-MEN1 PNETs are usually solitary pancreatic lesions that are diagnosed at 50-80 years of age, and ~50-75% of these will be associated with regional lymph node or distant hepatic metastasis at diagnosis 30, 31 . These differences between MEN1 and non-MEN1 PNETs make it difficult to extrapolate results of treatment outcomes from studies of non-MEN1 PNETs to MEN1 PNETs 15, 17 .
Current therapies for PNETs
Current PNET therapies in patients without MEN1 include medical drugs, surgery and radiological interventions FIG. 1) . Despite a lack of their formal evaluation in patients with MEN1, these treatments have been repurposed for treating PNETs in patients with MEN1 (REFS 15, 17) . Thus, the current treatments for PNETs in MEN1 are similar to those for PNETs in patients without MEN1, and evidence for their effectiveness comprises anecdotal case reports and small case series. These treatments and their limitations are briefly reviewed.
Medical therapies
Medical therapies for PNETs can be broadly divided into biotherapies (which target tumour-specific receptors and intracellular pathways) and chemotherapies (which generally target cell division) Biotherapies. Biotherapies for PNETs can be hormonal, and these are based on somatostatin, a peptide hormone that inhibits the release of other hormones, cell proliferation and angiogenesis 32 . In addition, biotherapies for PNETs can be targeted to tumour-specific molecular changes (for example, in receptors and signalling pathways) that promote tumour growth and spread, and these include mechanistic target of rapamycin (mTOR) signalling inhibitors, receptor tyrosine kinase (RTK) inhibitors and antibodies targeting the vascular endothelial growth factor (VEGF) or its receptor (VEGFR) 15 Somatostatin analogues (SSAs) (for example, octreotide and lanreotide) have been used to control excessive hormone secretion and for their potential anti-proliferative effects in patients with low-grade (Ki67 <5%) PNETs that express somatostatin receptors (SSTRs), which are G protein-coupled receptors [33] [34] [35] [36] . There are five SSTRs (SSTR1-SSTR5), and PNETs can express all five subtypes; however, ~80% of PNETs will predominantly express SSTR type 2 (SSTR2), which has a high affinity for octreotide and lanreotide 33 . Treatment with lanreotide has been reported to result in an ~50% reduction in the risk of disease progression and a prolonged progression-free survival (PFS) in patients without MEN1 who had treatment-naive well-differentiated advanced gastroentero-PNETs (the median PFS in the lanreotide-treated group was not reached compared with a median of 18 months in the placebo-treated group; P < 0.001) 35, 37, 38 (Supplementary information Table 1 ). This trial included 204 patients and excluded all patients with MEN1 (REF. 37 ). However, a retrospective evaluation of 40 patients with MEN1 and duodeno-PNETs treated with long-acting octreotide reported tumour response in 10% of patients, stable disease in 80% and progression of disease in 10% over 12-15 months of treatment 39 . These results suggest that SSA treatment may have some some anti-oncogenic benefits for patients with MEN1.
Approximately 15% of PNETs have somatic mutations of genes associated with the mTOR pathway 9 , which regulates cell proliferation and growth (FIGS. 1,3). The mTOR inhibitor everolimus has been reported to increase PFS from ~6 to 11 months in patients with advanced neuroendocrine tumours (NETs), including PNETs [40] [41] [42] [43] . This trial involved 401 patients, and the details of the occurrence of MEN1 and of mutations in the MEN1 gene or the genes that encode components of the mTOR pathway were not provided [40] [41] [42] . Thus, it remains to be established whether such mutations are associated with any differential responses to mTOR inhibitor therapy.
PNETs are highly vascularized and frequently express VEGFRs 44, 45 . RTK inhibitors (such as sunitinib and pazopanib) targeting VEGFRs and platelet-derived growth factor receptors (PDGFRs) have also been reported to increase PFS from ~5.5 to 11.4 months in patients with PNETs 46 . However, the efficacy of sunitinib in treating PNETs in patients with MEN1 remains to be evaluated. A trial comprising 171 patients included only 2 patients with MEN1, and these patients were not in the treatment arm of the study 46 . A phase II 
Current treatments
Current medical, surgical and radiological treatments have not been evaluated in patients with MEN1, but instead, successful therapies for endocrine tumours in patients without MEN1 have been extrapolated as treatments for patients with MEN1. However, the outcomes of such treatments in patients with MEN1 are greatly inferior to those in patients without MEN1. This difference in outcome might be due to the concomitant occurrence of multiple tumours in different glands, the presence of occult metastatic disease, the associated comorbidities that might decrease survival and the younger onset that could result in larger and more aggressive tumours that are resistant to treatment. Improved treatments for MEN1-associated tumours are required.
Emerging therapies
Increased understanding of the role of menin in cell proliferation has enabled targeted therapy of endocrine tumours in mouse models for NETs with MEN1 mutations. These treatments include adenoviral MEN1 gene replacement therapy, a hybrid adeno-associated virus and phage vector containing a ligand motif and tumour necrosis factor (TNF) transgene for tumour-directed therapy, epigenetic modulators, β-catenin antagonists targeting the wingless (WNT) pathway, thrombospondin 1 (TSP1) analogues, receptor tyrosine kinase inhibitors, mechanistic target of rapamycin (mTOR) inhibitors and somatostatin analogues (SSAs), which target a broad spectrum of receptors and might have a role in tumour chemoprevention.
trial pazopanib had a response rate of 20%, with either shrinkage of the tumours or stable disease occurring in >75% of patients without MEN1 who had metastatic gastroentero-PNETs 47 . Combination therapy using biotherapies that act on the different receptors and signalling pathways that regulate PNET proliferation and growth has been reported to result in beneficial effects and improved outcomes compared with monotherapy for gastrointestinal NETs and PNETs in patients without MEN1 and in patients whose MEN1 status was unknown 10, [48] [49] [50] [51] [52] [53] (Supplementary  information Table 1 ). Octreotide combined with everolimus increased PFS and decreased tumour size more often than did octreotide and placebo (75% versus 45% of the participants) in a phase III trial 48 , and octreotide with pazopanib resulted in tumour shrinkage in 22% of the participants in a phase II study 49 . In a phase II study, temsirolimus (an mTOR inhibitor) with bevacizumab (a monoclonal antibody directed at VEGF) reduced tumour size and increased PFS in >40% and ~80% of patients with PNETs, respectively 50 . An additional phase II study showed that bevacizumab, everolimus and octreotide increased PFS more than everolimus or octreotide alone in patients with PNETs 51, 52 . In a phase II monotherapy study, pasireotide (an SSA that targets SSTR2 and SSTR5) seemed to inhibit the growth of metastatic NETs, including PNETs 54 , but in this trial and in another phase I trial 55 , it was associated with hyper glycaemia and bradycardia in 30% and ~80% of patients, respectively. However, when pasireotide was used with everolimus in a phase I trial, tumour size decreased in >80% of the patients with unresectable or metastatic PNETs 53 . Some targeted therapies and their combinations, however, are not always successful. In a randomized trial treating metastatic gastroentero-PNETs, lanreotide with IFNα, which induces cell cycle arrest and also has anti-angiogenic effects, showed only anti-proliferative results that were similar to the effects of treatment with either lanreotide or IFNα alone 56 . Similarly, everolimus and octreotide combined with a monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R) was found to be unsafe and to not result in a PNET response during phase I and phase II trials [57] [58] [59] [60] [61] . IGF1R is an RTK that is expressed in PNETs, and it promotes cell proliferation by activation of phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB, also known as AKT) signalling and subsequently promotes mTOR activity. Blocking IGF1R impairs NET cell growth. In a phase II study, the use of octreotide in combination with bevacizumab and pertuzumab (a dimerization inhibitor of epidermal growth factor receptor HER1, which is overexpressed in NETs) failed to result in adequate response rates in patients with advanced PNETs 62 . In a phase II trial, dactolisib (an inhibitor of PI3K and mTOR complex 2, which is not inhibited by everolimus), when used alone, failed to improve outcomes in patients whose PNETs had progressed while previously on treatment with everolimus 63 . The use of these biotherapies varies in different international centres. Generally, SSAs (octreotide and lanreotide), the mTOR inhibitor everolimus and the RTK inhibitor sunitinib are accepted treatments for PNETs 64 .
Chemotherapy. Chemotherapy is reserved for patients who have metastasized PNETs, a high tumour burden, a high proliferative index (that is, a Ki67 value >5% or mitosis in >5 of 10 cells per high powered field), rapid tumour progression and/or symptoms not controlled by biotherapy 15, 65, 66 . Chemotherapy drugs can be classified into six categories, which act on different stages of mitosis (FIG. 1; BOX 2; Supplementary information Table 2 ). Drugs from each of these categories, except the nonclassic compounds, have been used to treat PNETs 15, 65, 66 and include alkylating agents, anti-microtubule agents, topoisomerase inhibitors, antimetabolites and cytotoxic antibiotics. Alkylating agents (for example, streptozocin, temozolomide and cisplatin) are cell cycle-independent drugs that covalently bind to DNA via their alkylating groups, disrupt DNA replication and cause apoptosis. Anti-microtubule agents (such as etoposide and docetaxel) disrupt the function of microtubules, which are required for cell division. Topoisomerase inhibitors (for example, doxorubicin and irinotecan) prevent the normal unwinding of DNA that is required during replication and transcription by blocking the activity of topoisomerase enzymes, which produce single or double-strand breaks in DNA and thereby reduce tension in the DNA strands that are adjacent to the unwound double-stranded DNA helix. Antimetabolites (for example, 5-fluorouracil (5FU), its pro-drug capecitabine, and gemcitabine) are cell cycle-dependent. They block enzymes required for DNA synthesis or are incorporated into DNA, thereby damaging it and inducing apoptosis. Cytotoxic antibiotics (such as actinomycin D, mitomycin C, doxorubicin and mitoxantrone), either alkylate DNA, become intercalated into DNA or generate highly reactive free radicals that damage intracellular molecules or inhibit topoisomerases.
Combination therapy using cytotoxic drugs acting on different cell cycle components results in better tumour responses than monotherapy in patients with PNETs. For example, regimens based on streptozocin or temozolomide have been reported to yield a response when compared with pretreatment tumour perimeters. Thus, studies in the 1990s reported that monotherapy with streptozocin and 5FU resulted in PNET response rates of ~40% and 35%, respectively 67 ; and combined therapies with streptozocin and either 5FU or doxorubicin resulted in response rates of >60% and ~70%, respectively 68 . However, these early studies used non-standard response rates, and more recent studies using WHO criteria and response evaluation criteria in solid tumours (RECIST) have reported lower PNET response rates of ~35% for streptozocin-based combined regimes 69 .
Temozolomide monotherapy resulted in PNET response rates of <10% 70 . Temozolomide combined with capecitabine was reported from a retrospective review to result in PNET response rates of ~60% 71 . Temozolomide, when combined with everolimus in a phase I/II study, resulted in tumour regression in 40% of patients with metastatic or locally unresectable PNETs 72 . Bevacizumab in combination with streptozocin or capecitabine, in phase II studies, improved PFS in patients with metastatic NETs, including PNETs [73] [74] [75] . None of these studies reported on the occurrence of MEN1 in the patients (Supplementary information Table 1 ).
Surgery
The ideal treatment for a non-metastatic single PNET is surgical excision, as this offers the only potentially curative treatment. However, surgery is often not as successful in patients with MEN1 as it is in those without MEN1 for the following reasons: first, there are usually multiple tumours in MEN1-associated PNETs (FIG. 2C) , with sizes varying from micro adenomas to >4 cm (REFS 4, 25, 76, 77) , making it difficult to achieve a successful surgical cure; and second, occult metastatic disease might be present 78 . In addition, the clinical behaviour of these PNETs also varies, and it is generally considered that all macroscopic PNETs are potentially malignant; however, the aggressiveness of an individual PNET cannot be accurately predicted by tumour size, radiological features or hormone production [79] [80] [81] . Additionally, studies have shown that most microadenomas are stable and infrequently increase in size; <20% of macroadenomas <2 cm will increase in size over 10 years; ~50-70% of PNETs of 2-3 cm will be associated with lymph node metastasis; and 25-40% of PNETs >4 cm will be associated with hepatic metastasis 21, 25, 30, 82, 83 . Survival in patients with MEN1 correlates with non-metastatic disease; for example, survival at 15 years in patients with MEN1 and gastrinomas <2.5 cm in size that are associated with non-metastatic disease or metastatic disease is reported to be 100% and 50%, respectively [82] [83] [84] [85] . Thus, the occurrence of multiple PNETs and their varied and unpredictable malignant potential in patients with MEN1 pose difficulties for the timing and extent of curative surgery. As a result of this, patients with MEN1-associated PNETs frequently require additional non-surgical treatments, such as biotherapies, chemotherapy (see previous section) or radiological therapies (see next section). 
Radiological treatments

Radiological therapies
Radiological therapies for PNETs include external beam radiotherapy, peptide receptor radionuclide therapy (PRRT) and interventional radiology 15, 64 PNETs are not sensitive to external beam radiotherapy, and PRRT is the preferred treatment 15, 65, 66 .
Peptide receptor radionuclide therapy. PRRT is usually based on an SSA (for example, octreotide, octreotate, DOTATATE and DOTATOC) that has been labelled with a β-emitting nuclide in the form of either lutetium-177 ( 177 Lu) or yttrium-90 ( 90 Y) 15, 86 . After SSTR binding (FIG. 1) and internalization of the receptor complex, the ionizing radiation is released, causing damage to tumour DNA and cell death. To date, the only results assessing the efficacy of PRRT in PNETs are from cohort studies of patients that have also included patients with other gastrointestinal NETs and metastatic NETs [87] [88] [89] [90] [91] [92] 92 , and the combination of 177 Lu-octreotate, capecitabine and temozolomide resulted in a complete or partial response in >50% of the patients with advanced NETs (including PNETs) in a phase I/II study 88 . FIG. 1 ) using radiofrequency ablation (RFA), transarterial embolization (TAE), transarterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) has been shown to be an effective treatment in selected cases of PNETs occurring in patients without MEN1 and for patients in whom the MEN1 status was not reported 64, [93] [94] [95] [96] [97] [98] [99] [100] (Supplementary information  Table 1 ). RFA is effective in treating primary PNETs in patients who are unable or unwilling to undergo surgical intervention 99 or have solitary PNET hepatic metastases 95 . TAE (which involves systemic infusion of micro particles that cause ischaemia and tissue necrosis) is effective for inoperable primary PNETs 97, 98 and hepatic PNET metastases 64 . Combining TAE of the hepatic artery with sunitinib in patients with PNETs resulted in a >65% increase in PFS and an ~60% increase in overall survival in a phase II study 100 . TACE combines TAE with locoregional chemotherapy. Hepatic metastases from gastrointestinal NETs (~40% were from PNETs) treated with TACE using doxorubicin-eluting beads was effective in a phase II study 93, 96 despite the treatment being associated with severe adverse effects 93 . TACE and TAE have similar antitumour effects, but post-embolization syndrome is more common with TACE treatment 94 . SIRT, which is used to deliver 90 Y-labelled spheres into the hepatic artery to provide local radiotherapy for hepatic metastases, was associated with objective tumour response in ~35% of patients and stable disease in ~55% of patients with NETs (10% of whom had PNETs) after 20 months 101 . Nature Reviews | Endocrinology These medical and radiological therapies should be effective in patients with MEN1, but they require formal evaluation, as the effects of comorbidities from other endocrine and non-endocrine tumours in patients with MEN1 might affect the outcomes. To date, the majority of trials have either excluded patients with MEN1 or included only occasional patients with MEN1 in the non-treatment arm (Supplementary information  Table 1 ). Thus, to facilitate re-purposing of these therapies, it is important that they are evaluated in patients with MEN1. In addition, new therapeutic modalities based on the function of menin might help in improving the outcome and prognosis for patients with MEN1.
Interventional radiology. Interventional radiology
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Emerging therapies for PNETs in MEN1
Therapies based on increased understanding of menin and the receptors and signalling pathways involved in the development of PNETs are emerging (BOX 1; FIG. 3) .
Assessment of the efficacy of such therapies has been facilitated by cellular and in vivo models, which include conventional and conditional Men1 knockout mouse models that develop MEN1-associated tumours, including PNETs [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] . Menin is a ubiquitously expressed protein that functions as a nuclear scaffold protein with roles in transcriptional regulation, genome stability, cell division, cell cycle control and epigenetic regulation [112] [113] [114] , which enables it to influence cellular proliferation pathways (FIG. 3) . Menin is known to inhibit wingless (WNT)-frizzled (FRZ) signalling by transferring β-catenin from the nucleus, which reduces cell proliferation 112, 115 . It is also known to affect the activity of transcription factor JUND by blocking its phosphorylation and therefore subsequent potential interactions with coactivators 113, 116 , which causes JUND to prevent rather than promote cell growth 117 . Menin can also inhibit ; binding to MLL1, MLL2 and SMAD3 (a TGFβ signalling component) to promote transcription of target genes [119] [120] [121] [122] [123] ; and ability to regulate the WNT pathway as β-catenin is no longer prevented from entering the nucleus by menin, thereby enabling transcription of WNT pathway target genes 112, 115 . In the cytoplasm, loss of menin reduces its inhibitory actions on: the mTOR pathway by binding to AKT (downstream of PI3K, part of the RTK (receptor tyrosine kinase) signalling pathway) and preventing its translocation to the plasma membrane 129; and KRAS-induced proliferation (by possible inhibition of ERK-dependent phosphorylation (P) and prevention of the interaction between SOS1 and KRAS) 125, 126 . Understanding the function of menin has identified potential new and targeted therapies (white boxes). These include the following: mTOR inhibitors; WNT pathway inhibitors (β-catenin antagonists); epigenetic modulators; MEN1 gene replacement (dark pink boxes); analogues of thrombospondin-1 (TSP1) that interact and alter TGFβ signalling, including the menin-interacting protein, SMAD3; RTK inhibitors; and SSAs (somatostatin (SST) analogues) that target a broader spectrum of somatostatin receptors (SSTRs). All pathways affect proliferation, which involves both nuclear and cytoplasmic mechanisms (shown in the cytoplasm only). Ligands are shown as green circles and receptors are yellow circles. FZR, frizzled; GF, growth factor; TGFβR, transforming growth factor β receptor. 
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Epigenetic modulators (e.g. targeting JUND, MLL1 and PRMT5) For example, VEGFR the Hedgehog signalling pathway, which influences several cellular functions including tumorigenesis. By recruiting protein arginine N-methyltransferase 5 (PRMT5), menin inactivates the Hedgehog pathway promoter growth arrest specific (GAS1) 118 . Moreover, menin interacts with the mixed-lineage leukaemia (MLL) histone methyltransferase complex to methylate histone H3 (at Lys4), causing chromatin modification and increased transcriptional activity of genes, including cyclin-dependent kinase inhibitors (CDKNs) p27 and p18 (which are encoded by CDKN1B and CDKN2C, respectively, and are involved in cell cycle regulation) 119, 120 . Menin also promotes the cytostatic effects of transforming growth factor-β (TGFβ) by interacting with the mothers against decapentaplegic homologue (SMAD) pathway [121] [122] [123] as well as by interacting with nuclear factor-κB (NF-κB) proteins to modulate NF-κB transactivation 124 . In addition, menin has roles that include interaction with the GTPase KRAS and sons of sevenless homologue 1 (SOS1), which prevents the KRAS-SOS1 interaction that is essential for KRAS activation 125 . Moreover, in murine pancreatic β-cells, menin activates opposing KRAS pathways consisting of a proliferative pathway (probably via regulation of mitogen-activated protein kinase (MAPK) signalling, also known as extracellular signal-regulated kinase (ERK) phosphorylation, which is downstream of serine/threonine-protein kinase BRAF) and an antiproliferative pathway via RAS-associated domain family member 1 isoform A (RASSF1A) 126 . Thus, menin is considered to interact with KRAS to block the dual specificity MAP/ERK kinase (MEK) pathway, thereby inhibiting proliferation, and menin loss removes this inhibition and leads to increased cell proliferation 126 . In addition, SSTR modulation of proliferation might also occur through KRAS signalling, thereby highlighting the importance of KRAS signalling in PNETs and indicating that menin could have a role in SSTR downstream signalling 127 . Menin also acts as a suppressor of ERK-dependent phosphorylation of target proteins 128 and an inhibitor of the mTOR signalling pathway by binding to AKT and preventing its translocation to the plasma membrane 129 . Some therapies emerging from preclinical studies that target these menin-specific pathways are discussed (FIG. 3) and include MEN1 gene therapy, epigenetic modulators, WNT signalling modulators and anti-angiogenic agents and the use of an SSA as a chemopreventive agent [130] [131] [132] [133] [134] [135] [136] [137] .
MEN1 gene therapy
The role of menin as a tumour suppressor was supported by in vitro studies demonstrating that menin overexpression in menin-null mouse embryonic fibroblasts (MEFs), RAS-transformed NIH3T3 MEFs and rat insulinoma cell lines resulted in decreased cell proliferation and increased apoptosis 129, [138] [139] [140] [141] . In addition, injection of RAS-transformed NIH3T3 MEFs (overexpressing menin) into athymic nude mice was associated with reduced tumour growth, further supporting a probable tumour suppressor role for menin in vivo 138 . These observations showed that over expression of menin could reduce proliferation and suggested that MEN1 gene replacement therapy could be efficacious. These findings were evaluated in a MEN1 mouse model using a recombinant non-replicating adenoviral serotype 5 vector (rAd5) containing Men1 cDNA under the control of a cytomegalovirus promoter (rAd5-Men1) 136 . To establish proof of principle for the efficacy of MEN1 gene therapy, the rAd5-Men1 vector was injected into pituitary NETs that developed in conventional hetero zygous Men1-knockout mice (Men1 +/-) 136 . This Men1 gene therapy resulted in increased menin expression with decreased proliferation of the pituitary NETs without inducing an immune response or increased apoptosis 136 . Moreover, the adenoviral gene therapy was not associated with increased mortality, and these results indicated the potential utility of MEN1 gene replacement therapy for in vivo treatment of MEN1-associated NETs 136 . The use of a hybrid adeno-associated virus and phage vector displaying biologically active octreotide on the viral surface for ligand-directed delivery of the pro-apoptotic tumour necrosis factor (TNF) transgene to PNETs developed in a pancreatic-specific conditional Men1-knockout mouse model (Pdx1-Cre) reduced tumour size and improved survival of the mutant mice 135 . These results suggest that systemic, ligand-directed transgene treatment could evolve as a novel and effective treatment of MEN1-related tumours.
Epigenetic modulators
Cancer is associated with alterations in epigenetic mechanisms such as histone modifications and DNA methylation. Epigenetic modulators represent a novel class of anticancer drugs 142 . Menin interacts with a number of histone modifying proteins, including histone methyltransferase (MLL1 and PRMT5; FIG. 3) and deacetylase complexes (for example, histone deacetylase complex subunit mSin3A) 11 . The use of epigenetic modulators to treat PNETs was assessed using JQ1 (an inhibitor of the bromodomain and extra terminal domain (BET) family of proteins that bind to acetylated histone residues to promote gene transcription) 143 . In vitro studies revealed that JQ1 decreased proliferation and increased apoptosis of PNET and bronchial NET cell lines 143 . These anti-proliferative effects of JQ1 were associated with increased numbers of NET cells in the G1 phase and decreased numbers in the S and G2 phases of the cell cycle 143 . Expression of histone 2B was also increased, which was probably mediated through altered activity of BET proteins 143 . Using a pancreatic β-cell-specific conditional Men1-knockout mouse model (RIP2-Cre) that develops PNETs, JQ1 was assessed in vivo 143 . In this Men1-knockout model, JQ1 decreased proliferation and increased apoptosis of PNETs 143 . CP103, another BET inhibitor, also reduced PNET proliferation in a human PNET cell line (BON-1) xenograft mouse model 144 . Thus, epigenetic modulators (for example, that function via BET inhibition) might offer potential therapies for MEN1-associated PNETs.
WNT signalling modulators
Menin inhibits WNT signalling, as it promotes phosphorylation of β-catenin and its transfer from the nucleus, which reduces cell proliferation 112, 115 (FIG. 3) .
Moreover, mice with conditional knockout of both β-catenin and menin in pancreatic β-cells (generated using a RIP-Cre mouse model) were found to have decreased number and size of PNETs as well as increased survival 132 . Furthermore, use of a β-catenin antagonist (PKF115-584) decreased PNET cell proliferation in β-cell menin-knockout mice 132 . These findings suggest that modulation of WNT signalling may be another approach for treatment of PNETs in patients with MEN1.
Anti-angiogenic compounds
The majority of anti-angiogenic compounds block the actions of VEGF, a cytokine that promotes the growth and survival of blood vessels. Treatment with bevacizumab (an anti-VEGF monoclonal antibody) in combination with chemotherapy delayed progression of moderately well-differentiated and advanced gastro intestinal NETs, which included metastatic, welldifferentiated PNETs [73] [74] [75] 145 . However, such inhibition of VEGF signalling has been reported to be accompanied by increased invasiveness and metastasis of cancers. This increased invasiveness and metastatic potential of cancers was observed in PNETs developing in a transgenic mouse model that expressed the large T antigen (Tag) under the control of the rat insulin promoter (RIP) and that had been rendered null for the recombination-activating gene 1 (Rag1) (RIP-Tag2, Rag1-knockout mice) 131 . This progression of the cancers and PNETs was reported to be associated with increased tumour hypoxia and expression of pro-angiogenic factors including vascular endothelial growth factor A (VEGFA), members of the fibroblast growth factor (FGF) family, ephrin A1 and proto-oncogene c-Met activation 131 . Treatment with RTK inhibitors (such as sunitinib) decreases the growth of PNETs in mice but increases tumour invasiveness and the incidence of liver metastases, which possibly occurs by upregulation of proangiogenic factors, including FGFs 146 . Thus, targeting FGFs, in addition to VEGF and PDGFR, might improve efficacy 130 . Furthermore, combining sunitinib, or an anti-VEGF antibody, with inhibitors (such as PF-04217903 or PF-0241066 (crizotinib)) of c-MET (which promotes cell proliferation, invasion and metastasis) prevented the increase in tumour aggressiveness without any impairment to restriction of tumour growth 147 . These findings indicate that the invasion and metastasis that are promoted by selective inhibition of VEGF signalling might be reduced by combined treatment with a c-MET inhibitor.
Inhibition of nitric oxide (NO) synthase might also be an option, as inhibition of NO synthase by l-arginine methyl ester (L-NAME) in PNETs from conventional Men1 +/-knockout mice in an ex vivo model impaired blood perfusion and increased constriction of the tumour supplying arterioles 148 . Thrombospondin 1 (TSP1) (FIG. 3) analogues might also be compounds of interest, as administration of TSP1 suppressed angiogenesis and tumour growth of PNETs in a transgenic mouse model (RIP-Tag2) 149 . It is interesting to note that menin interacts with SMAD3, which is downstream of the TSP1-TGFβ signalling pathway 150 .
SSAs for tumour chemoprevention
Cancer chemoprevention involves the chronic administration of a synthetic, natural or biological agent to reduce or delay the occurrence of tumours, and its value has been demonstrated in clinical trials involving patients with breast, prostate or colon cancer [151] [152] [153] [154] . Currently, individuals with a MEN1 mutation are entered into a screening programme for MEN1-associated tumours (including PNETs), commencing from the first or second decade of life 17 . This approach will detect tumours early, facilitating earlier treatment (such as with surgery), but will not prevent or delay the occurrence of tumours (that is, chemoprevention).
SSAs might have a role in chemoprevention of MEN1-associated NETs, as they have anti-proliferative and anti-secretory effects on NETs 37, 38, 155, 156 . Treatment with pasireotide (a multiple-receptor-targeted SSA that acts via SSTR1-SSTR3 and SSTR5 (REF. 33)) decreased proliferation and increased apoptosis of PNETs in Men1 +/-and Pdx1-Cre Men1-knockout mutant mice 134, 137 . Pasireotide also decreased proliferation and increased apoptosis of pituitary NETs in Men1 +/-mice and increased their survival 134, 137 . In addition to these anti-proliferative and pro-apoptotic effects, pasireotide inhibited the development of PNETs in the Men1 +/-mutant mice 137 . Thus, PNET occurrence was significantly lower in Men1 +/-mice treated with pasireotide than in Men1 +/-mice treated with control phosphate buffered saline (PBS) (87% of pasireotide-treated mice versus ~97% of PBS-treated mice; P < 0.05) 137 . Moreover, the mean number of PNETs per pancreas was also significantly lower in the pasireotide-treated Men1 +/-mice than in the PBS-treated Men1 +/-mice (2.36 ± 0.25 in pasireotide-treated versus 3.72 ± 0.32 in PBS-treated; P < 0.001) 137 . These findings indicate that pasireotide treatment resulted in fewer Men1 +/-mice with PNETs and fewer PNETs per pancreas than were seen in PBStreated Men1 +/-mice, and are consistent with a lower development of new NETs in pasireotide-treated Men1 +/-mice 137 . Moreover, the pasireotide-treated Men1 +/-mice appeared healthier and had increased survival compared with the placebo-treated Men1 +/-mice, and adverse effects from the pasireotide treatment were not detected 137 . These findings suggest that SSAs might have a chemopreventive role in the treatment of MEN1-associated PNETs in humans, and two studies have reported that SSAs have anti-proliferative actions in PNETs of patients with MEN1 (REFS 39, 157) . In one study, octreotide was given to patients with MEN1 to treat duodeno-PNETs, and retrospective analysis revealed that 10% of PNETs showed a tumour response and that 80% of patients had stable disease 39 . In another study, octreotide was given prospectively to eight patients with MEN1 and gastroenteroPNETs 157 . Octreotide was reported to be safe, to decrease gastrointestinal hormone secretion and to be associated with stable PNET disease 157 .
Conclusions
MEN1 is an autosomal dominant disorder caused by mutations of the MEN1 gene, which encodes the tumour suppressor protein menin. MEN1 is characterized by the occurrence of PNETs in association with tumours in different endocrine glands such as the parathyroids, pituitary and adrenals. The associated hypersecretion of hormones and malignant potential of these tumours, especially PNETs, severely reduces the life expectancy of patients with MEN1. Current medical, surgical and radiological treatments for PNET patients with MEN1, which are based on their effectiveness in treating PNETs in patients without MEN1, are associated with inferior outcomes. Increased understanding of the role of menin, which is the protein encoded by the MEN1 gene, in tumorigenesis and cell proliferation has enabled targeted therapies to be identified. These new treatments have been evaluated in preclinical studies and include adenoviral MEN1 gene replacement therapy, epigenetic modulators, β-catenin antagonists targeting the WNT pathway, TSP1 analogues and a multiple-receptor-targeted SSA. Clinical evaluation of such emerging treatments targeting menin-associated pathways might provide new therapies for improving outcomes and life expectancy in patients with MEN1.
